Given the prognostic homogeneity of POLEmut cases, POLE mutation status adds minimal independent predictive value beyond classical clinicopathological features (early FIGO stage, absent/subfocal LVSI, small tumor size, preserved hormone receptors, negative peritoneal cytology, etc.). This evidence concerns the gene NR4A1 and neoplasm.